11.05.2016 curasan AG  DE0005494538

DGAP-News: curasan posts sales growth in the first quarter


 
DGAP-News: curasan AG / Key word(s): Quarterly / Interim Statement curasan posts sales growth in the first quarter 11.05.2016 / 08:34 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- - Adjusted gross revenues increase by 2.5 percent to 1.63 million euros - EBITDA declines due to lower other operating income and increased personnel costs to -0.33 million euros - Cash flow pressured by period accruals curasan AG (ISIN DE0005494538), a leading specialist for medical products in the field of orthobiologics, concluded the first quarter of fiscal year 2016 with slight increases in revenues. Adjusted gross revenues increased by 2.5 percent to 1.63 million euros compared to the same period in 2015. The reason for the repeated adjustment in gross revenues is the cessation of sales activities for the unprofitable product Cytoplast. Final revenues of 0.13 million euros resulted from the sale of the remaining inventories in the first quarter of 2015. The result before taxes, interest, depreciation and amortization (EBITDA) decreased to -0.33 million euros from -0.07 million euros in the previous year. This was due on the one hand to a non-recurring effect from currency translation gains amounting to 0.13 million euros resulting from the debt consolidation from the American subsidiary curasan inc. in the comparable period of the previous year. On the other hand, personnel costs rose as planned in line with the growth strategy. Operative cash flow at -0.88 million was significantly below the figure of -0.43 million for the previous year. The difference, which was larger than planned, is largely due to accruals-based accounting. "In the second half of March, our revenues grew significantly. However, we will be able to post the corresponding payments received only in the second quarter," explained Michael Schenk, CEO of curasan AG. "Such shifts can always occur at the end of a period, but are mostly compensated by this point." The successful completion of a required animal study for the FDA certification of CERASORB sent positive signals. Several clinical studies in dental and orthopedic surgery were launched simultaneously with the application for regulatory approval. In addition, the company hosted the "Frankfurt Implantology Days" for the first time again in March. "In recent years we did not hold this event due to cost pressures. The feedback from the participating implantologists, surgeons and speakers regarding the revival of the event was resoundingly positive. Next year we will expand the Frankfurt Implantology Days to include international participants and speakers," said Schlenk. During the event, clinical physicians and university researchers exchanged information with interested and experienced users regarding their extensive long-term experience with the synthetic bone regeneration material CERASORB. For the first time, curasan will hold a Global Sales Meeting in a similar form from May 26-28. The objective is to provide the company's international distributors not only with more information about the products but particularly with innovative and practical marketing concepts. The complete interim report on the first quarter of 2016 is available for downloading on the company's website. Instead of holding a telephone conference, CEO Michael Schlenk is available to interested investors, analysts and members of the press at the DVFA Spring Conference in Frankfurt am Main and will be making a group presentation and holding individual conferences. Upcoming capital market events of curasan AG: 11 May 2015 DVFA Spring Conference, Frankfurt am Main 12 May 2015 Roadshow in Cologne/Düsseldorf About curasan AG: curasan AG develops, manufactures and markets biomaterials and other medical products in the field of bone and tissue regeneration. A pioneer in its industry, curasan is specialized primarily on synthetic bone grafting materials for dental and orthopaedic applications. Numerous patents and a comprehensive list of scientific documentation prove the clinical success of the products and the highly innovative strength of curasan. Surgically active dentists, implantologists and oral, maxillary and dentofacial surgeons, as well as orthopaedics, traumatologists and spinal column surgeons worldwide benefit from the broad range of the premium quality and user-oriented portfolio offered by the technology leader. curasan maintains its own high-tech facilities for research, development and manufacturing in Frankfurt/Main, Germany, which are approved by the Food and Drug Administration (FDA) and other international authorities. In addition to its headquarters, the company has a subsidiary, curasan Inc., in the Research Triangle Park, near Raleigh, N.C., USA.The shares of curasan AG are listed in the General Standard at the Frankfurt Stock Exchange. www.curasan.com Contact: Ingo Middelmenne Head of Investor Relations Tel. +49 6027 40900-45 Fax +49 6027 40900-39 ingo.middelmenne@curasan.de Andrea Weidner Head of Corporate Communications Tel. +49 6027 40900-51 Fax +49 6027 40900-39 andrea.weidner@curasan.de www.curasan.de --------------------------------------------------------------------------- 11.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: curasan AG Lindigstraße 4 63801 Kleinostheim Germany Phone: 06027/40 900 0 Fax: 06027/40 900 29 E-mail: info@curasan.de Internet: www.curasan.de ISIN: DE0005494538 WKN: 549453 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------------- 462325 11.05.2016


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 3,23 5,82 5,76 5,97 6,93 6,80 5,84 6,40
EBITDA1,2 -2,97 -1,64 -1,12 2,13 -2,14 -2,22 -3,84 -3,00
EBITDA-Marge3 -91,95 -28,18 -19,44 35,68 -30,88 -32,65 -65,75 -46,88
EBIT1,4 -3,32 -2,14 -1,83 1,33 -2,66 -2,84 -4,78 -2,80
EBIT-Marge5 -102,79 -36,77 -31,77 22,28 -38,38 -41,76 -81,85 -43,75
Jahresüberschuss1 -3,47 -2,14 -1,83 1,33 -2,09 -4,00 -5,38 -2,50
Netto-Marge6 -107,43 -36,77 -31,77 22,28 -30,16 -58,82 -92,12 -39,06
Cashflow1,7 -2,72 -1,85 -0,37 2,15 -2,11 -2,55 -4,34 0,00
Ergebnis je Aktie8 -1,53 -0,90 -0,72 0.45 -0,63 -0,99 -0,99 -0,33
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Hinrik J. Schröder

INVESTOR-INFORMATIONEN
©boersengefluester.de
Curasan
WKN Kurs in € Einschätzung Börsenwert in Mio. €
549453 0,470 Verkaufen 4,26
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 15,55 0,000 0,00
KBV KCV KUV EV/EBITDA
0,57 - 0,73 -1,204
Dividende '18 in € Dividende '19e in € Div.-Rendite '18
in %
Hauptversammlung
0,00 0,00 0,00 26.06.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
23.05.2019 22.08.2019 21.11.2019 13.05.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
14,63% -17,54% -7,84% -48,91%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu curasan AG  ISIN: DE0005494538 können Sie bei DGAP abrufen

Gesundheit , 549453 , CUR , XETR:CUR